Gershon Capital provides emerging life science companies with direct investment, syndicated equity and debt financings, licensing opportunities, royalty monetization, strategic partnering, and M&A advisory.
We conduct a rigorous due diligence on the company, arrange investor meetings, negotiate with syndicated investors, and structure and close the transaction.
Healthcare & Life Science Companies
The firm seeks to work with healthcare and life science companies with therapeutic, medical device, healthcare IT products and healthcare services that meet unmet clinical needs and possess disruptive technology.
Our clients typically posses the following attributes:
– Breakthrough technology based on strong science
– Experienced and well-rounded management team with a proven track record in successfully commercializing new products and technologies
– Strong and comprehensive IP portfolio
– Partnerships with leading academic institutions and strategic players
– Product or technology that permits company valuation at exit to be between $150M and $750M USD within three to five years of investment